Research programme: anti-infectives - Kemin

Drug Profile

Research programme: anti-infectives - Kemin

Alternative Names: KPE 00001048; KPE 00001125; KPE 01001001; KPE 01001014; KPE00000297; KPE00000313; KPE03003015; KPE03003017; KPE03003028; KPE05001

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kemin Pharma
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Bacterial infections; Mycoses

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Belgium
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mycoses in Belgium
  • 23 Sep 2008 Preclinical development is ongoing in Belgium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top